The Journal of clinical investigation 1950 Aug
Iron metabolism; hematopoiesis following phlebotomy; iron as a limiting factor.
Related Questions
How do you anticipate rusfertide (VERIFY trial) will be used in the management of polycythemia vera?
Do you think it will become first-line therapy? Is potential iron overload a concern with long-term use?
New answer by at Johns Hopkins University (July 15, 2025)
Rusfertide, an injectable hepcidin mimetic (1), is another new arrow in the quiver of 21st-century therapies for controlling erythropoiesis without phlebotomy in polycythemia ...